Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 176.50p 173.00p 180.00p 176.50p 176.50p 176.50p 23,927 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.6 -9.5 -0.4 - 237.96

Arix Bioscience Share Discussion Threads

Showing 51 to 75 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
14/9/2018
14:01
Looks like a pretty impressive Board appt...
skyship
21/8/2018
15:32
Have doubled my holding with one buy at 158.50 and one at 172.
chesil356
21/8/2018
13:19
Bought this morning at 1.63 The Proactive interview is very good. See www.proactiveinvestors.co.uk/companies/stocktube/10188/artios-in-strong-position-to-accelerate-cancer-programmes-after-arix-investment-10188.html
brexitplus
21/8/2018
11:57
Nice to see this edging back up. There was comment yesterday including two broker forecasts of 253p and 314p. hxxp://www.proactiveinvestors.co.uk/companies/news/203218/arix-bioscience-share-sale-explains-recent-market-disconnect-say-brokers-203218.html
pdt
21/8/2018
08:38
Can't even buy £500 worth of these online and market makers buying above the bid.Looks like they are now short of stock to sell.
chesil356
18/8/2018
21:57
what about directors /management COMP running at circa £5m pa? That's £50m over the next 10 years for a market cap business of only £200+ Seems an outrageous level of remuneration.....
kristini2
17/8/2018
20:13
A new interview on Proactive site explaining reasons behind investment in Artios, worth a listen; hxxp://www.proactiveinvestors.co.uk/companies/stocktube/10165/arix-sees-significant-potential-as-it-ups-stake-in-cancer-treatment-developer-artios-10165.html Syncona are trading above NAV and we are considerably below NAV. With the Seller seemingly done for a while these will hopefully rise back to the 200p area I would have thought. However, nothing surprises me any more! Rambutan2 - ha, ha PDT are just my initials!
pdt
17/8/2018
14:16
PDT (prelude trust?), that's a good spot on Artios.
rambutan2
17/8/2018
14:15
Yes, that overhang is almost certainly the reason and I'd expect to start heading north from here before too long: LONDON, 17 August 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, was notified today that Christopher Chipperton has today sold 3,000,000 ordinary shares of GBP 0.00001 nominal value each ("Ordinary Shares") at a price of 155 pence per Ordinary Share (the "Disposal"). As a result of the Disposal Christopher Chipperton is interested, in aggregate, in 7,147,914 Ordinary Shares in the Company representing 5.3 per cent. of the Company's issued share capital. Christopher Chipperton (the "Locked-in Party") has entered into a lock-in agreement (the "Agreement") pursuant to which he shall not dispose of any interest in Ordinary Shares (held directly or indirectly) for a period of 12 months following the Disposal, save in certain very limited circumstances. The Agreement also provides that, save in certain limited circumstances, the Locked-in Party shall not dispose of any interest in Ordinary Shares (held directly or indirectly) for a period of 12 months following the first anniversary of the Disposal unless such disposal is effected through Stifel Nicolaus Europe Limited ("Stifel"), in order to ensure an orderly market in the Ordinary Shares ("Orderly Market Period"). Any disposal of Ordinary Shares during the Orderly Market Period will be in such a manner as Stifel may reasonably require with the view to the maintenance of an orderly market.
rambutan2
17/8/2018
13:16
Does today's news of a 3m share sale explain the recent decline in the share price? On a separate note I saw a positive article on the work being undertaken by Artios in today's Daily Mail; hTTp://www.dailymail.co.uk/news/article-6068949/New-cancer-pill-stops-tumor-cells-repairing-making-sensitive-radiotherapy.html
pdt
17/8/2018
09:50
I had a top up at 157p this morning although it shows on here as a Sell on the trade list. There does seem to be a disconnect between NAV and the market cap.
pdt
16/8/2018
21:06
AUTL closes at $30 today. So stake value is £74m. At 158p close, ARIX mkt cap is £215m. So AUTL currently constitutes a third of mkt cap. Chuck in the approx £120m of cash and £7m (as at close) in ITRM, and that's leaving very little value put on everything else owned.
rambutan2
11/8/2018
08:20
I see Autolus was up 8% on friday and has been rising over the last 3 weeks. I added to my small holding here at the end of last week. Feel confident that this will get back to 200p plus at some point over the next 18 months so happy to be patient.
pdt
10/8/2018
19:40
I see what you mean, this level of comp for a business of this size and level of development appear excessive...........
kristini2
10/8/2018
02:56
Re ITRM: “We are delighted to begin our first Phase 3 clinical trial for sulopenem early in the third quarter, consistent with our prior guidance. The commencement of our Phase 3 program marks an important milestone for our company,” said Corey Fishman, Chief Executive Officer of Iterum. “We are leveraging our prior clinical trial data, and the important feedback we received from the FDA and European regulators, to conduct our Phase 3 trials, with data expected to readout in the second half of 2019. If approved, oral sulopenem would be the first new drug approved for uncomplicated UTIs in over 20 years and would provide a much-needed treatment option in a large and growing market.” http://uk.advfn.com/stock-market/NASDAQ/ITRM/share-news/Iterum-Initiates-SURE-1-a-Phase-3-Clinical-Trial/78045894
rambutan2
10/8/2018
02:49
kristini2, see pages 60-64 of the annual report below. But suffice to say, the execs are clearly believers in the greed is good maxim! httPs://arixbioscience.com/wp-content/uploads/2018/04/Arix-Bioscience-AR2017-FINAL-web.pdf
rambutan2
09/8/2018
13:30
Ram what are the annual salaries being taken here do you know? K
kristini2
07/8/2018
19:19
My very approx back of the envelope calc says that for £230m mkt cap you are getting: £60m in AUTL £74m in 13 other interesting companies, 3 of which are listed. £120m cash A highly experienced, albeit highly expensive board/management team.
rambutan2
07/8/2018
18:58
I wonder whether under pressure Woodford are dripping out a few, along with private investors (supposedly 4000 of them) who bought in at ipo and are now bored.
rambutan2
07/8/2018
16:43
I have just bought my first holding here. Attracted by the Pharmaxis investment. I was considering buying Pharmaxis direct but this way I have spread the risk. Why is it trading below NAV ? The management seem experienced and well connected and a nice spread of investments.
pdt
06/8/2018
17:56
Undervalued? hxxp://www.proactiveinvestors.co.uk/companies/news/202119/arix-biosciences-progress-significantly-undervalued-suggests-us-broker-202119.html
alcimedes
06/8/2018
14:32
First VIPE and looks interesting: hTtp://www.pharmaxis.com.au/assets/Documents/pdf/02018/ASX/2018-08-06-PXS-Placement-Announcement-FINAL.pdf htTp://www.pharmaxis.com.au/
rambutan2
01/8/2018
20:00
Half year nav was 191p. Not sure why ARIX is now trading at a discount, but gritted my teeth and bought a few at 174p today. (For ref, edison ipo initiation note: https://www.edisoninvestmentresearch.com/research/report/arix-bioscience/preview/ )
rambutan2
01/8/2018
19:50
Whilst even more recent IPO Autolus stays well above $17 listing price: http://uk.advfn.com/p.php?pid=quote&symbol=autl Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its largest Group Business holding Autolus Therapeutics plc ("Autolus") has today announced the closing of its previously announced initial public offering ("IPO") in the United States of 10,147,059 American Depositary Shares ("ADSs"), representing 10,147,059 ordinary shares, at an initial public offering price of $17.00 per ADS, which includes an additional 1,323,529 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. All of the ADSs were offered by Autolus. Following the IPO, Arix retains a stake of 7.9% in Autolus (amounting to 3,161,533 ordinary shares), which was valued at $82.8m (GBP62.4m)[1] at the close of business on 25 June 2018. So, at today's $24, the stake is worth £59m.
rambutan2
01/8/2018
19:46
Recent IPO Iterum struggling a bit at mo, but very early days: http://uk.advfn.com/p.php?pid=quote&symbol=itrm Arix Bioscience plc ("Arix", LSE: ARIX) a global healthcare and life science company supporting medical innovation, today (May 30) notes that its Group Business Iterum Therapeutics plc ("Iterum", NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today closed its initial public offering of 6,150,000 of its ordinary shares at an initial offering price to the public of $13.00 per share. All of the shares were offered by Iterum. The shares are listed for trading on the Nasdaq Global Market under the symbol "ITRM". Arix has invested $4.4 million (GBP3.3 million) in Iterum's IPO. Following completion of the offering, Arix holds a stake of approximately 7.4 percent of the issued and outstanding shares of Iterum (amounting to 1,031,903 ordinary shares). Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "Iterum was founded in 2015 with the ambition to develop an antibiotic that addresses the growing crisis of multi-drug-resistant pathogens, and today we see it reach an important milestone towards reaching that goal. We believe Iterum has considerable potential to deliver important new treatment options to patients and we are excited to support the company's next stage of growth and development."
rambutan2
Chat Pages: 3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180919 02:47:33